title: Intravitreous ranibizumab as treatment for macular telangiectasia type 2.
authors.affiliation: State University of Campinas, Unicamp, Recife, Brazil. rodrigopclira@hotmail.com
authors.forename: Rodrigo Pessoa Cavalcanti
authors.initials: RP
authors.lastname: Lira
authors.forename: Valdir Balarin
authors.initials: VB
authors.lastname: Silva
authors.forename: Tiago Marques
authors.initials: TM
authors.lastname: Cavalcanti
authors.forename: Ana Catarina Delgado
authors.initials: AC
authors.lastname: de Souza
authors.forename: Alexandre Paashaus da Costa
authors.initials: AP
authors.lastname: Pinto
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008875:Middle Aged; D000069579:Ranibizumab; D012160:Retina / Q000473:pathology; D012163:Retinal Detachment / Q000175:diagnosis / Q000503:physiopathology; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D013684:Telangiectasis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab